The evaluation and management of patients with cancer with suspected immune checkpoint inhibitor (ICI) colitis have distinct challenges within the setting of the coronavirus disease 2019 (COVID‐19) pandemic. The approach to the treatment of patients with ICI colitis requires consideration of the risks and benefits of individual immunosuppressive medications and varies based on the presence of a concurrent COVID‐19 infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461305 | PMC |
| http://dx.doi.org/10.1002/cncr.33125 | DOI Listing |
Publication Analysis
Top Keywords
ici colitis
8
management immunotherapy
4
immunotherapy colitis
4
colitis special
4
special considerations
4
considerations covid-19
4
covid-19 era
4
era evaluation
4
evaluation management
4
management patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!